Cardiovascular health

Preventive genetic test against cardiovascular diseases

The test analyzes polymorphisms involved in oxidative stress, hypertension, homocysteine, lipid metabolism disorders and thrombosis.

CARDIOgen can be carried out in case of a family history of cardiovascular diseases, suspicion of cardiovascular diseases, lipid and homocysteine metabolism disorders and arterial hypertension.

This test is carried out on a sub-contracted basis by an accredited laboratory.

Innovative blood test to determine the individual risk of stroke and heart attack

The PLAC® test is an innovative risk marker that measures the enzymatic activity of Lp-PLA2 (lipoprotein-associated phospholipase A2), a specific biomarker for vascular inflammation involved in the formation of unstable plaques that cause majority of cardiovascular events. 

This easy blood test for the detec­tion of Lp-PLA2 offers a more individual risk assess­ment than the usual examinations. Approximately 70% of the heart attacks and most of the strokes are caused by rupture of vascular de­posits, also called atherosclerotic plaques.

Who should be tested and when?

Men ≥ 45; women ≥ 55 with at least 2 of these risk factors:

• Hypertension
• History of cardiovascular diseases or diabetes
• Overweight
• Increased cholesterol levels
• Smoking
• Lack of exercise

Results and Interpretation

The determination of Lp-PLA2 (a vessel-specific inflammation enzyme) shows if plaques are located within the arte­rial vessel wall that tend to rupture. The PLAC®-Test results allow to stratify the individual risk of a patient and ad­just the treatment depending on the results.

Additional information:

The PLAC^®-Test is a CE-labelled test.

Preventive genetic test against atherosclerosis

The test analyzes genetic polymorphisms known to be involved in the development of atherosclerosis as well as in its underlying causes such as lipid metabolic disorders. LIPIDgen is recommended to people with a family history of type III familial hypercholesterolemia or atherosclerosis, or if the patient presents very high levels of HDL, LDL or total cholesterol.

This test is carried out on a sub-contracted basis by an accredited laboratory.

Preventive genetic test against deep vein thrombosis

The test analyzes polymorphisms involved in hemostasis, thrombus formation and in the folate metabolism. The information obtained with the profile allows early action in order to decrease the relative risk of thrombosis. THROMBOgen is indicated in case of family history of thrombosis, prior to oral contraception, in case of repetitive spontaneous abortions and atherosclerosis in young people.

This test is carried out on a sub-contracted basis by an accredited laboratory.

Homocysteinemia

A thermolabile variant of the methylenetetrahydrofolate reductase, caused by a mutation at position 677, is associated with an increased homocysteine level. An increased homocysteine level can increase the risk of developing thrombosis and atherosclerosis.

This test is carried out on a sub-contracted basis by an accredited laboratory.

Fatty acid nutrition and metabolism can influence inflammation risks. The test analyzes the variations in genes associated with utilization of fatty acids. The results can be used by doctors to recommend the optimal nutrition or supplementation in regard to omega3/6 fatty acid metabolism for the individual patient.

This test is carried out on a sub-contracted basis by an accredited laboratory.

OPTIMETgen is a panel of SNPs related to methylation and detoxification efficiencies. Based on the results, personalized recommendations are provided to optimize metabolic cycles of the methyl groups. These recommendations are also beneficial in the prevention of age-related diseases and aging.

This test is carried out on a sub-contracted basis by an accredited laboratory.